Latest Market News

Dateline Resources reaffirms its Colosseum Gold-REE Project metrics and economics while navigating ongoing legal proceedings involving its CEO and rare earth tenements in the US.

Metallium Limited has resumed trading on the ASX following news of a significant collaboration and funding deal with a US partner to advance its critical-metals recovery technology.

Metallium Ltd has secured a strategic partnership with ElementUSA to deploy its Flash Joule Heating technology for recovering gallium and scandium from red mud in Louisiana, backed by US$10.1 million in non-dilutive funding. This collaboration positions Metallium at the forefront of the US critical minerals supply chain expansion.

National Storage REIT has announced a fully franked 6 cent dividend for the second half of 2025, while withdrawing all prior guidance due to a significant scheme announcement.

IGO Limited’s subsidiary has confirmed its commitment to Stage 2 of the farm-in at the Bridgetown-Greenbushes Project, pledging $3 million to increase its ownership to 70%. Extensive soil sampling has revealed a significant lithium-tantalum-niobium-cesium anomaly, underpinning the project's promising exploration outlook.

4DMedical has locked in $30.2 million through an underwriting agreement ensuring full exercise of its listed options, lifting its cash reserves to $63.7 million and setting the stage for a pivotal year in commercialising its CT – VQ™ technology.

Artrya Limited has begun generating fee-per-scan revenues from its Salix Coronary Plaque module at Tanner Health in the U.S., marking a key commercial milestone for the AI-powered cardiac imaging platform.

Vita Life Sciences forecasts solid sales and profit growth for FY2025, driven by strong performances in Malaysia and Singapore, while cautiously managing challenges in China exports.

Voltaic Strategic Resources confirms a significant 1.2km surface rare earth element and gallium anomaly at its Soren prospect within the Paddys Well Project, setting the stage for an extensive 2026 drilling and geophysical campaign.

Acrux Limited has sold the US registration and distribution rights for its Prilocaine 2.5% and Lidocaine 2.5% cream for US$550,000, redirecting resources towards its growing Hormone Replacement Therapy portfolio.

Rhythm Biosciences has begun commercialising ColoSTAT®, its blood-based colorectal cancer diagnostic test, following an updated ISO15189, 2022 accreditation. The test offers a new option for symptomatic patients where stool-based screening is unsuitable.

HITIQ has secured a prestigious grant from the Australian Sports Commission to enhance its PROTEQT™ brain health monitoring technology, positioning the company for wider adoption across elite and community sports.